[{"id":"1fd7db54-93ac-41e4-bc56-3603227c89e8","acronym":"ROCKET","url":"https://clinicaltrials.gov/study/NCT02096354","created_at":"2021-01-18T09:40:38.201Z","updated_at":"2024-07-02T16:36:10.444Z","phase":"Phase 2","brief_title":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02096354 - ROCKET","lead_sponsor":"EpicentRx, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • irinotecan • nibrozetone (RRx-001)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 04/13/2018","study_completion_date":" 04/13/2018","last_update_posted":"2022-05-16"}]